Guangzheng Lin1, Ling Ning2, Di Gu1, Shi Li1, Zhe Yu1, Qicheng Long1, Li-Na Hou3, Wan-Long Tan1. 1. Department of Urology, Nanfang Hospital, Southern Medical University Guangzhou 510515, Guangdong, P. R. China. 2. Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University Guangzhou 510515, Guangdong, P. R. China. 3. Department of Health Management, Nanfang Hospital, Southern Medical University Guangzhou 510515, Guangdong, P. R. China.
Abstract
OBJECTIVE: To examine the relationship between circulating 25-hydroxy-vitamin D (25 (OH) D) and risk of kidney cancer. METHODS: We searched PubMed, EMBASE, and Web of Science databases through August 31, 2015 for eligible studies. Pooled ORs with 95% confidence interval were calculated using fixed effect models. All data analyses were performed with STATA version 12.0. RESULTS: The final analysis included 2 prospective cohort studies and 7 nested case-control studies, with a total of 130, 609 participants and 1, 815 cases of kidney cancer. No obvious heterogeneity was observed between individual studies. The results of this study revealed that higher circulating 25-hydroxyvitamin D levels were associated with lower risk of kidney cancer (OR=0.79, 95% CI 0.69-0.91; P value for heterogeneity: 0.61, I(2)=0%). After stratified by geographical region, the similar association was detected in European studies (OR=0.81, 95% CI 0.69-0.94; P value for heterogeneity: 0.38, I(2)=0%), though no significant association was observed in the USA studies (OR=0.73, 95% CI 0.51-1.04; P value for heterogeneity: 0.44, I(2)=0%). CONCLUSION: Our present findings suggest that higher levels of circulating 25-hydroxyvitamin D could reduce the risk of kidney cancer by 21%. Further well-designed large-scaled prospective studies and randomized controlled trials are warranted to provide more conclusive evidence.
OBJECTIVE: To examine the relationship between circulating 25-hydroxy-vitamin D (25 (OH) D) and risk of kidney cancer. METHODS: We searched PubMed, EMBASE, and Web of Science databases through August 31, 2015 for eligible studies. Pooled ORs with 95% confidence interval were calculated using fixed effect models. All data analyses were performed with STATA version 12.0. RESULTS: The final analysis included 2 prospective cohort studies and 7 nested case-control studies, with a total of 130, 609 participants and 1, 815 cases of kidney cancer. No obvious heterogeneity was observed between individual studies. The results of this study revealed that higher circulating 25-hydroxyvitamin D levels were associated with lower risk of kidney cancer (OR=0.79, 95% CI 0.69-0.91; P value for heterogeneity: 0.61, I(2)=0%). After stratified by geographical region, the similar association was detected in European studies (OR=0.81, 95% CI 0.69-0.94; P value for heterogeneity: 0.38, I(2)=0%), though no significant association was observed in the USA studies (OR=0.73, 95% CI 0.51-1.04; P value for heterogeneity: 0.44, I(2)=0%). CONCLUSION: Our present findings suggest that higher levels of circulating 25-hydroxyvitamin D could reduce the risk of kidney cancer by 21%. Further well-designed large-scaled prospective studies and randomized controlled trials are warranted to provide more conclusive evidence.
Authors: Robin Taylor Wilson; Jiangyue Wang; Vernon Chinchilli; John P Richie; Jarmo Virtamo; Lee E Moore; Demetrius Albanes Journal: Am J Epidemiol Date: 2009-08-03 Impact factor: 4.897
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Mazda Jenab; H Bas Bueno-de-Mesquita; Pietro Ferrari; Franzel J B van Duijnhoven; Teresa Norat; Tobias Pischon; Eugène H J M Jansen; Nadia Slimani; Graham Byrnes; Sabina Rinaldi; Anne Tjønneland; Anja Olsen; Kim Overvad; Marie-Christine Boutron-Ruault; Françoise Clavel-Chapelon; Sophie Morois; Rudolf Kaaks; Jakob Linseisen; Heiner Boeing; Manuela M Bergmann; Antonia Trichopoulou; Gesthimani Misirli; Dimitrios Trichopoulos; Franco Berrino; Paolo Vineis; Salvatore Panico; Domenico Palli; Rosario Tumino; Martine M Ros; Carla H van Gils; Petra H Peeters; Magritt Brustad; Eiliv Lund; María-José Tormo; Eva Ardanaz; Laudina Rodríguez; Maria-José Sánchez; Miren Dorronsoro; Carlos A Gonzalez; Göran Hallmans; Richard Palmqvist; Andrew Roddam; Timothy J Key; Kay-Tee Khaw; Philippe Autier; Pierre Hainaut; Elio Riboli Journal: BMJ Date: 2010-01-21